ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.0
  1. ホーム
  2. /反応

Diisopropylethylamine → N-((S)-1-(3-bromo-6-(3-hydroxy-3-methylazetidin-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide

HRID 2170379
ノート
印刷プレビュー

反応式

HRID 2170379 の反応式
[F:1][CH:2]([F:18])[C:3]1[C:4]2[C@H:14]3[CH2:15][C@H:13]3[C:12]([F:17])([F:16])[C:5]=2[N:6]([CH2:8][C:9](O)=[O:10])[N:7]=1.[NH2:19][C@H:20]([C:30]1[N:35]=[C:34]([N:36]2[CH2:39][C:38]([CH3:41])([OH:40])[CH2:37]2)[CH:33]=[CH:32][C:31]=1[Br:42])[CH2:21][C:22]1[CH:27]=[C:26]([F:28])[CH:25]=[C:24]([F:29])[CH:23]=1.CN(C(ON1N=NC2C=CC=NC1=2)=[N+](C)C)C.F[P-](F)(F)(F)(F)F.C(N(CC)C(C)C)(C)C>CN(C=O)C>[Br:42][C:31]1[C:30]([C@@H:20]([NH:19][C:9](=[O:10])[CH2:8][N:6]2[C:5]3[C:12]([F:17])([F:16])[C@@H:13]4[CH2:15][C@@H:14]4[C:4]=3[C:3]([CH:2]([F:18])[F:1])=[N:7]2)[CH2:21][C:22]2[CH:27]=[C:26]([F:28])[CH:25]=[C:24]([F:29])[CH:23]=2)=[N:35][C:34]([N:36]2[CH2:39][C:38]([OH:40])([CH3:41])[CH2:37]2)=[CH:33][CH:32]=1
参加物反応条件実験手順後処理出典と根拠反応ノート

参加物

6

反応物 4

HCID 81531DiisopropylethylamineHCID 9886157Methanaminium, N-((dimethylamino)(3H-1,2,3-triazolo(4,5-b)pyridin-3-yloxy)methylene)-N-methyl-, hexafluorophosphate(1-) (1:1)HCID 90280371(S)-1-(6-(1-amino-2-(3,5-difluorophenyl)ethyl)-5-bromopyridin-2-yl)-3-methylazetidin-3-olHCID 902812892-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid

生成物 1

HCID 90281188
N-((S)-1-(3-bromo-6-(3-hydroxy-3-methylazetidin-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide

試薬・触媒・溶媒 1

HCID 6228Dimethylformamide溶媒

反応条件

温度
0 °C

実験手順

2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid (33 mg, 0.13 mmol), (S)-1-(6-(1-amino-2-(3,5-difluorophenyl)ethyl)-5-bromopyridin-2-yl)-3-methylazetidin-3-ol (50 mg, 0.13 mmol) and HATU (57 mg, 0.15 mmol) were dissolved in 1 mL of DMF and cooled to 0° C. To it was dropwise added N,N-diisopropylethylamine (0.07 mL, 0.38 mmol). The reaction mixture was allowed to stir at 0° C. for 5 min, and then partitioned between EtOAc and 5% LiCl aqueous solution. The organic layer was separated, washed with NaHCO3 (saturated aqueous) and brine. After dried over MgSO4, it was filtered and concentrated. The residue was purified by silica gel chromatography eluting with EtOAc/hexanes to afford the title product. MS (m/z): 644.33[M+H]+.

後処理

  1. custompartitioned between EtOAc and 5% LiCl aqueous solution
  2. customThe organic layer was separated
  3. washwashed with NaHCO3 (saturated aqueous) and brine
  4. dry with materialAfter dried over MgSO4, it
  5. filtrationwas filtered
  6. concentrationconcentrated
  7. customThe residue was purified by silica gel chromatography
  8. washeluting with EtOAc/hexanes

出典と根拠

ORDレコード
ord-24fca7582daf4a0f992ad2dcd475646b
出典データセット
uspto-grants-2015_06
DOI
10.6084/m9.figshare.5104873.v1
特許番号
US09050344B2

反応ノート

読み込み中…

このページの内容参加物反応条件実験手順後処理出典と根拠反応ノート